Qian Linfeng, Zheng Junnan, Xu Hongfei, Shi Liping, Li Lanjuan
Department of Cardiothoracic Surgery, the First Affiliated Hospital, Zhejiang University Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Medicine (Baltimore). 2016 Oct;95(40):e5052. doi: 10.1097/MD.0000000000005052.
Patients with respiratory failure caused by H7N9 may benefit from veno-venous, veno-arterial, and veno-veno-arterial extracorporeal membrane oxygenation (ECMO) support.
A 55-year-old male patient was suffering from H7N9-caused acute respiratory distress syndrome (ARDS). He had a mechanical mitral and aortic valve replacement surgery and was using warfarin for anticoagulation. After prolonged mechanical ventilation, oxygen saturation was not improved. Veno-veno ECMO was then applied. After 16 days of extracorporeal life support, the patient successfully weaned from ECMO, with relatively good pulmonary recovery.
This report demonstrates that ECMO support can help treating life-threatening diseases such as H7N9-associated ARDS. Because of his special mitral and aortic valve replacement surgery history and long duration of mechanical ventilation before ECMO, we report it as a separate case, hoping to provide some reference for ECMO treatment.
H7N9所致呼吸衰竭患者可能从静脉-静脉、静脉-动脉和静脉-静脉-动脉体外膜肺氧合（ECMO）支持中获益。
一名55岁男性患者患有H7N9所致急性呼吸窘迫综合征（ARDS）。他曾接受二尖瓣和主动脉瓣置换机械手术，且正在使用华法林进行抗凝。经过长时间机械通气后，氧饱和度未得到改善。随后应用了静脉-静脉ECMO。经过16天的体外生命支持，患者成功脱离ECMO，肺部恢复情况相对良好。
本报告表明，ECMO支持有助于治疗诸如H7N9相关ARDS等危及生命的疾病。鉴于其特殊的二尖瓣和主动脉瓣置换手术史以及在ECMO之前长时间的机械通气，我们将此作为一个单独病例报告，希望为ECMO治疗提供一些参考。
